Canada - English - Health Canada

natco pharma (canada) inc - pomalidomide - capsule - 3mg - pomalidomide 3mg

Canada - English - Health Canada

apotex inc - pomalidomide - capsule - 3mg - pomalidomide 3mg

Canada - English - Health Canada

dr reddy's laboratories ltd - pomalidomide - capsule - 3mg - pomalidomide 3mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pomalidomide, quantity: 3 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; maltodextrin; sodium stearylfumarate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; indigo blue; shellac - pomalidomide sandoz, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. pomalidomide sandoz, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior threatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - pomalidomide, quantity: 3 mg - capsule - excipient ingredients: pregelatinised maize starch; mannitol; sodium stearylfumarate; iron oxide black; shellac; propylene glycol; strong ammonia solution; ethanol absolute; purified water; butan-1-ol; isopropyl alcohol; indigo carmine; iron oxide yellow; titanium dioxide; gelatin - pomalyst, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. pomalyst, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Canada - English - Health Canada

natco pharma (canada) inc - pomalidomide - capsule - 3mg - pomalidomide 3mg

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - pomalidomide 3mg;   - capsule - 3 mg - active: pomalidomide 3mg   excipient: gelatin indigo carmine iron oxide yellow mannitol pregelatinised maize starch sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - pomalidomide, quantity: 3 mg - capsule, hard - excipient ingredients: pregelatinised starch; sodium stearylfumarate; mannitol; croscarmellose sodium; titanium dioxide; indigo carmine; purified water; iron oxide yellow; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - pomalidomide, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 3 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 3 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide